Skip to main content


About Insights

Our robust database offers access to Health Economics & Outcomes Research (HEOR) studies, patient journey reports, provider targeting lists, enterprise data license, and beyond

Amplity Insights networks with various real-world evidence data sources to compile an unparalleled database of information, providing a unique perspective on patient conditions and provider interactions.

Our data serve as a supplemental source of powerful qualitative data not found elsewhere. The records offer an intimate view of the patient-provider interaction and provide valuable insights including:
  • Factors influencing a provider’s treatment rationale
  • The efficacy and outcome of treatment interventions
  • Treatment pathways and trends
  • Patient-reported outcomes and voice-of-patient
  • Disease progression

Assessing Prevalence of Hypoglycemia in a Medical Transcription Database

The following publication developed by Novo Nordisk and leveraging Amplity Insights' unique medical transcription database supports the hypothesis that hypoglycemia is underreported in traditional claims or electronic medical record (EMR) databases. Using an unstructured and nonbillable database allowed Novo Nordisk to gain a more in-depth understanding of hypoglycemia and its prevalence.

Closing the Insight Gaps Left by Structured EMR Datasets

While structured datasets from EMR systems serve an important business need and provide analytical value, they leave large gaps related to patient characteristics and treatment decisions. Fortunately, dictated medical transcription records (unstructured data), when mined effectively using leading digital processes, provide a much richer on-the-ground view of patient care at a level of detail unavailable from any other source.

The Database

Our data covers over 150,000 physicians from over 40,000 clinics and hospitals across all 50 US states

The data contain much less bias than other sets, and Amplity Health receives data from academic hospitals, small hospitals, and clinics of all sizes. We are agnostic to electronic medical record (EMR) systems and insurance providers. Example use cases of the database include:


  • Medical intervention and outcomes evaluation provider and patient profiling
  • Identification of treatment patterns and decisions
  • Disease progression and intervention efforts
  • Market research
  • Clinical trial patient recruitment and provider identification
  • Clinical trial protocol feasibility


  • Commercial planning and messaging
  • Measure marketing and sales force effectiveness
  • Market sizing
  • Sales force planning and messaging
  • Data-driven physician profiling
  • Measure sales force effectiveness
  • Increase physician awareness and education efforts

Customer targeting

  • Target providers based on any patient criteria including:
    • Single or symptom combinations
    • Comorbid conditions
    • Prescription drugs
    • OTC medications
    • Diagnosis
    • Test results
    • Procedures or therapies
    • Event dates
  • Locate geographic regions where relevant patients are being treated
  • Follow patient activity on an ongoing basis
  • Assess protocol feasibility

Commercial Insights

Amplity Insights gives you actionable insights to help you make more informed strategic decisions while gaining a competitive advantage

Amplity Insights provides clients with a unique data set that offers new insight into patient-provider interactions and a deeper understanding of provider-treatment rationale.

How Amplity Insights can help

By leveraging Amplity Insights, in conjunction with our commercial solutions, the field sales teams benefit from increased insight into trends, while being armed with specific messaging to address competitive threats.

This data can be distributed by geographic region to illuminate current market dynamics. This gives you a real-world understanding of the WHY behind clinical decision-making and patient behaviors.

Case example

We provide detailed data regarding why patients may be discontinuing medication or if they are switching to a competing product.

Market situation

During a new drug launch, our client wanted to understand prescribing trends and the effectiveness of awareness campaigns.
understand prescribing trends

Real insights from physician interactions

  • Insights into discontinuations

    Insights into discontinuations

    “We did discuss the case with him, and we did try to give him Treatment A at that point, which was given only for 2 cycles due to his renal function abnormality. He became so confused. His mental status changed, and he did not want to take Treatment B anymore. That was stopped and there was improvement in his mental status. We would like to add immunomodulatory agent again, but unfortunately, he had significant side effects of CNS toxicity due to Treatment A, which occasionally can occur."
  • Insights into discontinuations

    Insights into discontinuations

    “Due to significant side effects of Treatment A, it had to be discontinued after barely a few months… I do not believe that he can receive Treatment A in the future due to his severe fatigue that is associated, and also pancytopenia that seems to be associated, with Treatment A. Now he has been off all treatment for the last 3 weeks and he feels much better.”
  • Insights into discontinuations

    Insights into discontinuations

    "Other possibilities to add Treatment A, but again the patient is not very enthusiastic about it. After much discussion, we have decided to continue Treatment B and go ahead and add the Treatment C again 20 mg weekly for the next 4 weeks and then see what happens in the next 4 weeks. If he complains of more neuropathy and the disease starts to progress, then obviously we are going to have to go to second-line treatment, which may include either again possibility of adding Treatment A or going to Treatment D, etc.”

    Measuring the impact of awareness campaign efforts

    The following chart demonstrates how many times providers have mentioned 2 drugs over a set period of time. This is particularly powerful during drug launches or marketing campaigns as it captures a unique measurement of brand and efficacy awareness.
    Measuring the impact of awareness campaign efforts

    Key takeaway

    We can see that, over time, following the approval of Treatment B as a first-line treatment for multiple myeloma, the trend shows a reduction of Treatment A mentions and an increase in Treatment B mentions, suggesting some displacement of Treatment A market share.

    Health Economics and Outcomes Research (HEOR) Insights

    Amplity Insights provides a more complete picture of the true patient journey

    Clinical decisions made by healthcare providers are dependent upon the evaluation of several key indicators.

    Lab test results, imaging results, treatment efficacy, progression of disease, patient-reported symptomatology, and access to care may all play a role in driving treatment decisions.

    However, these meaningful data endpoints are not readily captured in commercially available real-world structured databases such as claims or EMR. Amplity Insights is not dependent upon billable events that are captured by charge codes submitted to payors for reimbursement.

    The Amplity Insights database contains the full unstructured narratives of patient-provider encounters as dictated by healthcare providers daily.

    Using our proprietary Natural Language Processing (NLP) algorithms, meaningful data endpoints may be quickly extracted and evaluated for specific research questions. Leveraging this rich source of patient-level data, researchers are able to glean insights related to the true prevalence of disease, treatment patterns, rationale for treatment, and patient-reported outcomes.

    See how our data was used to understand if the prevalence of hypoglycemia might be underreported in other medical data sources.

    Click the button below for excerpts from a peer-reviewed publication.

    "A unique database with valuable insights, AmplityInsights has been my go-to database for complex questions or when the most up-to-date information is needed."
    - HEOR Strategist from one of our Medical Affairs and Market Access Consultancy clients